SarcomaPhase 1/2NCT00023725
Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue Sarcoma
A Phase 1/2 study testing semaxanib, conventional surgery and radiation therapy in people with Sarcoma, run by Radiation Therapy Oncology Group at 226 sites in 2 countries.
Trial summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if radiation therapy is more effective with or without SU5416 in treating soft tissue sarcoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Sarcoma
- What is being tested?
- semaxanib, conventional surgery and radiation therapy
- Type of treatment
- Surgery or procedure
- How many people
- Not given
- Where
- 226 sitesin 2 countries
- Study dates
- Aug 2001to Oct 2003
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically confirmed primary or locally recurrent stage IB or IIA soft tissue sarcoma
- Grade 1 or 2
- Tumor greater than 5 cm in diameter
- Tumor located on upper extremities (including shoulder), lower extremities (including hip), or body wall
- No sarcoma of the head and neck or intra-abdominal or retroperitoneal sarcoma
- No desmoid tumor or dermatofibrosarcoma protuberans
- No metastatic disease
- No evidence of lung metastases
- Maximum of 4 lung lesions no greater than 5 mm in diameter each on preoperative chest CT scan allowed OR
- Lesion no greater than 1 cm allowed if stable for at least 1 year and fits criteria for granuloma
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Zubrod 0-1
Life expectancy:
- At least 2 years
Hematopoietic:
- WBC at least 4,000/mm^3 OR
- Absolute neutrophil count at least 1,800/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 mg/dL
- SGOT no greater than 50 U/L
- PT and PTT less than 1.25 times normal (not on warfarin)
Renal:
- Creatinine no greater than 1.5 mg/dL OR
- Creatinine clearance greater than 50 mL/min
Cardiovascular:
- No congestive heart failure or myocardial infarction within the past 6 months
- No uncompensated coronary artery disease
- No severe peripheral vascular disease
- No peripheral vascular disease with diabetes mellitus
- No deep venous or arterial thrombosis within the past 3 months
- Fibrin split products less than 2 times normal
- Fibrinogen greater than 200 mg/dL
Pulmonary:
- No pulmonary embolism within the past 3 months
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No contraindications to surgery
- No active uncontrolled bacterial, viral, or fungal infection
- No other prior or concurrent malignancy within the past 5 years except surgically treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer
- No other serious medical or psychiatric illness that would preclude informed consent
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior biologic therapy for soft tissue sarcoma
Chemotherapy:
- No prior chemotherapy for soft tissue sarcoma
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy for soft tissue sarcoma
Surgery:
- At least 2 weeks since prior minor surgery (e.g., port placement)
- At least 4 weeks since prior major surgery
Trial locations and contacts
226 sites in 2 countries.
226 sites in 2 countries
United States207 sites
Akron General Medical Center
Akron, Ohio, 44302
Akron City Hospital
Akron, Ohio, 44309
Cancer Center of Albany Medical Center
Albany, New York, 12208
Radiation Oncology Associates of Albuquerque
Albuquerque, New Mexico, 87109
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103
Harrington Cancer Center
Amarillo, Texas, 79106
St. John's Medical Center
Anderson, Indiana, 46016
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
Anne Arundel Oncology Center
Annapolis, Maryland, 21401
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, 21204
Harbor Hospital Center
Baltimore, Maryland, 21225
Sinai Hospital of Baltimore
Baltimore, Maryland, 21225
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
St. Luke's Hospital Regional Cancer Center
Bethlehem, Pennsylvania, 18015
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
Bloomington Hospital
Bloomington, Indiana, 47402
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
State University of New York Health Science Center at Brooklyn
Brooklyn, New York, 11203
New York Methodist Hospital
Brooklyn, New York, 11215-3609
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Vermont Cancer Center
Burlington, Vermont, 05401-3498
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Cancer Center at the University of Virginia
Charlottesville, Virginia, 22908
Northwestern Memorial Hospital
Chicago, Illinois, 60611
Christ Hospital
Cincinnati, Ohio, 45219
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45267-0502
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
University Hospitals of Cleveland
Cleveland, Ohio, 44106
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Finger Lakes Radiation Oncology Center
Clifton Springs, New York, 14432
Memorial Hospital Cancer Center
Colorado Springs, Colorado, 80909
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
Medical Center/John B. Amos Community Cancer Center
Columbus, Georgia, 31902
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
Mount Diablo Medical Center
Concord, California, 94524-4110
Northeast Medical Center
Concord, North Carolina, 28025
Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Fitzgerald Mercy Hospital
Darby, Pennsylvania, 19023
CCOP - Central Illinois
Decatur, Illinois, 62526
University of Colorado Cancer Center
Denver, Colorado, 80010
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Henry Ford Hospital
Detroit, Michigan, 48202
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000
Wendt Regional Cancer Center of Finley Hospital
Dubuque, Iowa, 52001
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07018-1095
Pocono Cancer Center
East Stroudsburg, Pennsylvania, 18301
John F. Kennedy Medical Center
Edison, New Jersey, 08818
Trinitas Hospital - Jersey Street Campus
Elizabeth, New Jersey, 07201
McLaren Regional Cancer Center
Flint, Michigan, 48432
Hurley Medical Center
Flint, Michigan, 48503
California Cancer Center
Fresno, California, 93720
Saint Agnes Cancer Center
Fresno, California, 93720
University of Florida Health Science Center
Gainesville, Florida, 32610-0296
University of Texas Medical Branch
Galveston, Texas, 77555-0209
Saint Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
St. Vincent Hospital
Green Bay, Wisconsin, 54307-3508
Sutter Health West Cancer Research Group
Greenbrae, California, 94904
East Carolina University School of Medicine
Greenville, North Carolina, 27858-4354
CCOP - Greenville
Greenville, South Carolina, 29615
RMH Regional Cancer Center
Harrisonburg, Virginia, 22801
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
MBCCOP - Hawaii
Honolulu, Hawaii, 96813
University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030-4009
Huntsville Hospital System
Huntsville, Alabama, 35801-4470
Comprehensive Cancer Institute of Huntsville
Huntsville, Alabama, 35801
Cape Cod Hospital
Hyannis, Massachusetts, 02601
Veterans Affairs Medical Center - Indianapolis (Roudebush)
Indianapolis, Indiana, 46202
Clarian Health Partners Inc.
Indianapolis, Indiana, 46206-1367
Community Hospitals of Indianapolis - Regional Cancer Center
Indianapolis, Indiana, 46219
Jackson-Madison County General Hospital
Jackson, Tennessee, 38301
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
CCOP - Kansas City
Kansas City, Missouri, 64131
CCOP - Dayton
Kettering, Ohio, 45429
Gundersen Lutheran Medical Foundation
La Crosse, Wisconsin, 54601
Wilford Hall - 59th Medical Wing
Lackland Air Force Base, Texas, 78236-5300
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756-0002
Central Baptist Hospital
Lexington, Kentucky, 40503
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
Loma Linda University Medical Center
Loma Linda, California, 92354
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
Monmouth Medical Center
Long Branch, New Jersey, 07740-6395
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
James Graham Brown Cancer Center
Louisville, Kentucky, 40202
Louisville Radiation Oncology
Louisville, Kentucky, 40215
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, 79410-1894
Southern Wisconsin Radiotherapy Center
Madison, Wisconsin, 53713
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Merle M. Mahr Cancer Center
Madisonville, Kentucky, 42431
Elliot Regional Cancer Center
Manchester, New Hampshire, 03103
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Marquette General Hospital
Marquette, Michigan, 49855
Marshfield Clinic
Marshfield, Wisconsin, 54449
Loyola University Medical Center
Maywood, Illinois, 60153
Health First Holmes Regional Medical Center
Melbourne, Florida, 32901
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, 38103
Community Memorial Hospital
Menomonee Falls, Wisconsin, 53051
Veterans Affairs Medical Center - Miami
Miami, Florida, 33125
Sylvester Cancer Center, University of Miami
Miami, Florida, 33136
Baptist Hospital of Miami
Miami, Florida, 33176-2197
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
MidMichigan Medical Center - Midland
Midland, Michigan, 48670
South Jersey Regional Cancer Center
Millville, New Jersey, 08332
Columbia Hospital
Milwaukee, Wisconsin, 53211
St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Trinity Cancer Care Center
Minot, North Dakota, 58701
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
Alabama Oncology, LLC
Montgomery, Alabama, 36106-2801
Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County
Mount Holly, New Jersey, 08060
Ball Memorial Hospital
Muncie, Indiana, 47303-3499
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232-6838
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Tulane University School of Medicine
New Orleans, Louisiana, 70112
CCOP - Ochsner
New Orleans, Louisiana, 70121
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Newark Beth Israel Medical Center
Newark, New Jersey, 07112
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
St. Anthony Hospital
Oklahoma City, Oklahoma, 73101
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73190
Methodist Cancer Center - Omaha
Omaha, Nebraska, 68114
Nebraska Health System
Omaha, Nebraska, 68198-7460
Florida Radiation Oncology Group
Orange Park, Florida, 32073
MD Anderson Cancer Center Orlando
Orlando, Florida, 32806
Bay Medical Center
Panama City, Florida, 32401
Gulf Coast Cancer Treatment Center
Panama City, Florida, 32405-4587
Lutheran General Cancer Care Center
Park Ridge, Illinois, 60068
Huntington Cancer Center
Pasadena, California, 91105
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104-4283
Veterans Affairs Medical Center - Philadelphia
Philadelphia, Pennsylvania, 19104
Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, 19107-5541
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, 19141
Foundation for Cancer Research and Education
Phoenix, Arizona, 85013
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213-3489
Mercy Hospital of Pittsburgh
Pittsburgh, Pennsylvania, 15219
Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224
Champlain Valley Physicians Hospital Medical Center
Plattsburgh, New York, 12901
Cancer Care Center
Pomona, California, 91767
Atlantic City Medical Center
Pomona, New Jersey, 08240
Maine Medical Center
Portland, Maine, 04102
CCOP - Columbia River Program
Portland, Oregon, 97213
Naval Medical Center, Portsmouth
Portsmouth, Virginia, 23708-2197
Vassar Brothers Hospital
Poughkeepsie, New York, 12601
Roger Williams Medical Center/BUSM
Providence, Rhode Island, 02908-4735
Southeastern Wisconsin Regional Cancer Center
Racine, Wisconsin, 53405
Reading Hospital and Medical Center
Reading, Pennsylvania, 19612-6052
Bon-Secours - St. Mary's Hospital
Richmond, Virginia, 23226
Massey Cancer Center
Richmond, Virginia, 23298-0037
Valley Hospital
Ridgewood, New Jersey, 07450
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
University of Rochester Cancer Center
Rochester, New York, 14642
Regional Radiation Oncology Center at Rome
Rome, Georgia, 30165
William Beaumont Hospital
Royal Oak, Michigan, 48073
Radiation Oncology Center - Sacramento
Sacramento, California, 95816
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Peninsula Regional Medical Center
Salisbury, Maryland, 21801
University of Utah Health Sciences Center
Salt Lake City, Utah, 84132
Latter Day Saints Hospital
Salt Lake City, Utah, 84143
Radiation Medical Group, Inc.
San Diego, California, 92101-1492
UCSF Cancer Center and Cancer Research Institute
San Francisco, California, 94143-0128
O'Connor Hospital
San Jose, California, 95128
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, 95403
Sarasota Radiation and Medical Oncology Center
Sarasota, Florida, 34233
Mercy Hospital Cancer Center - Scranton
Scranton, Pennsylvania, 18501
Virginia Mason Medical Center
Seattle, Washington, 98111
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
CCOP - Upstate Carolina
Spartanburg, South Carolina, 29303
Deaconess Medical Center
Spokane, Washington, 99210-0248
Cancer Research for the Ozarks
Springfield, Missouri, 65807
CCOP - Cancer Research for the Ozarks
Springfield, Missouri, 65807
Mallinckrodt Institute of Radiology
St Louis, Missouri, 63108
St. Louis University Health Sciences Center
St Louis, Missouri, 63110-0250
Dixie Regional Medical Center
St. George, Utah, 84770
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
Syracuse, New York, 13217
Tallahassee Memorial Healthcare
Tallahassee, Florida, 32308
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
Community Medical Center
Toms River, New Jersey, 08755
David Grant Medical Center
Travis Air Force Base, California, 94535
St. Francis Medical Center
Trenton, New Jersey, 08629
William Beaumont Hospital - Troy
Troy, Michigan, 48098
St. John Health System
Tulsa, Oklahoma, 74104
Radiation Oncology Associates of West Alabama
Tuscallosa, Alabama, 35401
Associated Radiologists, P.A.
Warren Township, New Jersey, 07059
Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188
Schiffler Cancer Center
Wheeling, West Virginia, 26003
Wilkes Barre General Hospital
Wilkes-Barre, Pennsylvania, 18764
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
CCOP - Southeast Cancer Control Consortium
Winston-Salem, North Carolina, 27104-4241
Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, 27157-1082
Yakima Valley Memorial Hospital
Yakima, Washington, 98902
Riverhill Radiation Oncology
Yonkers, New York, 10701
York Hospital
York, Pennsylvania, 17315
Canada19 sites
Tom Baker Cancer Center - Calgary
Calgary, Alberta, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
CHUS-Hopital Fleurimont
Fleurimont, Quebec, J1H 5N4
Northeastern Ontario Regional Cancer Centre, Sudbury
Greater Sudbury, Ontario, P3E 5J1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2
Kingston Regional Cancer Centre
Kingston, Ontario, K7L 5P9
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2L-4M1
McGill University
Montreal, Quebec, H2W 1S6
Ottawa Regional Cancer Centre
Ottawa, Ontario, K1H 1C4
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, G1R 2J6
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Newfoundland Cancer Treatment and Research Foundation
St. John's, Newfoundland and Labrador, A1B 3V6
Northwestern Ontario Regional Cancer Centre, Thunder Bay
Thunder Bay, Ontario, P7A 7T1
Toronto Sunnybrook Regional Cancer Centre
Toronto, Ontario, M4N 3M5
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
About this study
Official title: A Randomized Phase I/II Study Of Preoperative Radiotherapy With/Without SUGEN 5416 (NSC # 696819; A TK Inhibitor Anti-Angiogenesis Compound) In The Management Of Low To Intermediate Grade Soft Tissue Sarcoma Of The Trunk or Extremity
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if radiation therapy is more effective with or without SU5416 in treating soft tissue sarcoma.
PURPOSE: Phase I/II trial to compare the effectiveness of radiation therapy with or without SU5416 in treating patients who have stage IB or stage IIA soft tissue sarcoma.
Read the detailed description
OBJECTIVES:
- Determine the maximum tolerated dose of SU5416 when combined with neoadjuvant radiotherapy in patients with stage IB or IIA soft tissue sarcoma.
- Determine the antiangiogenic effects of SU5416 in these patients.
- Determine any synergistic antiangiogenic effect of SU5416 with radiotherapy in these patients.
- Compare the disease-free survival, local recurrence, distant metastases, and overall survival rates in patients treated with neoadjuvant radiotherapy with or without SU5416.
OUTLINE: This is a phase I dose-escalation study of SU5416 followed by a phase II randomized study.
Phase I:
- Patients undergo radiotherapy once daily, 5 days a week, for 5 weeks. Patients also receive SU5416 IV over 1 hour twice weekly beginning on week 1 and continuing until 2 days before surgery.
- Cohorts of 3-6 patients receive escalating doses of SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Phase II:
- Once the MTD has been determined, additional patients are accrued and then randomized to receive either treatment as in phase I at the MTD vs preoperative radiotherapy alone.
All patients undergo surgical resection 70-80 days after beginning therapy. Patients with positive surgical margins receive additional radiotherapy daily for 8 days and SU5416 IV over 1 hour on days 2, 4, and 9.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 18 patients will be accrued for phase I of this study within 1 year. Approximately 28 patients will be accrued for phase II of this study.
- Conditions
- Sarcoma
- Being tested
- semaxanib, conventional surgery, radiation therapy
- Keywords
- stage I adult soft tissue sarcoma
- Medical subject headings
- Sarcoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
semaxanibDrug
conventional surgeryProcedure or surgery
radiation therapyRadiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2003 (estimated)
- Study startAug 2001
- Study completionOct 2003
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
Sponsor and investigators
- Lead sponsor
- Radiation Therapy Oncology Group
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Burton L. Eisenberg, MD, Study chair, Fox Chase Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00023725
- Sponsor's protocol ID
- CDR0000068854
- Other IDs
- RTOG-S-0120
- Status last verified
- Aug 2007
- First submitted
- 13 Sep 2001
- Last updated
- 24 Jun 2013
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase I/II Study Of Preoperative Radiotherapy With/Without SUGEN 5416 (NSC # 696819; A TK Inhibitor Anti-Angiogenesis Compound) In The Management Of Low To Intermediate Grade Soft Tissue Sarcoma Of The Trunk or Extremity
- ClinicalTrials.gov ID
- NCT00023725
- Acronym / sponsor ID
- CDR0000068854
- Conditions
- Sarcoma
- Keywords
- stage I adult soft tissue sarcoma
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Completed
- Lead sponsor
- Radiation Therapy Oncology GroupResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Aug 2001
- Study completion
- Oct 2003 (actual)
- First posted
- 15 Oct 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor. It is not yet known if radiation therapy is more effective with or without SU5416 in treating soft tissue sarcoma.
PURPOSE: Phase I/II trial to compare the effectiveness of radiation therapy with or without SU5416 in treating patients who have stage IB or stage IIA soft tissue sarcoma.
Detailed description
OBJECTIVES:
- Determine the maximum tolerated dose of SU5416 when combined with neoadjuvant radiotherapy in patients with stage IB or IIA soft tissue sarcoma.
- Determine the antiangiogenic effects of SU5416 in these patients.
- Determine any synergistic antiangiogenic effect of SU5416 with radiotherapy in these patients.
- Compare the disease-free survival, local recurrence, distant metastases, and overall survival rates in patients treated with neoadjuvant radiotherapy with or without SU5416.
OUTLINE: This is a phase I dose-escalation study of SU5416 followed by a phase II randomized study.
Phase I:
- Patients undergo radiotherapy once daily, 5 days a week, for 5 weeks. Patients also receive SU5416 IV over 1 hour twice weekly beginning on week 1 and continuing until 2 days before surgery.
- Cohorts of 3-6 patients receive escalating doses of SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Phase II:
- Once the MTD has been determined, additional patients are accrued and then randomized to receive either treatment as in phase I at the MTD vs preoperative radiotherapy alone.
All patients undergo surgical resection 70-80 days after beginning therapy. Patients with positive surgical margins receive additional radiotherapy daily for 8 days and SU5416 IV over 1 hour on days 2, 4, and 9.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 18 patients will be accrued for phase I of this study within 1 year. Approximately 28 patients will be accrued for phase II of this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| semaxanib | Drug | – |
| conventional surgery | Procedure or surgery | – |
| radiation therapy | Radiation | – |
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2013.
Related trials for Sarcoma
RecruitingPhase 2
A Multicenter Phase II Clinical Trial Evaluating 68Ga-HX01 Injection for PET/CT Imaging
Soft Tissue Sarcoma
RecruitingPhase 3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1/2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Lymphoma, Waldenström Macroglobulinemia (WM)
Enrolling by invitationPhase 1
Evaluation of the I-phase Clinical Trial of 177Lu-HX02 Injection in Patients With Advanced Malignant Solid Tumors
Soft Tissue Sarcoma, Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Burton L. Eisenberg, MD study chair
Fox Chase Cancer Center
226 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing semaxanib, conventional surgery and radiation therapy in people with Sarcoma, run by Radiation Therapy Oncology Group at 226 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 226 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2013.